Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipps - William Blair Divya Rao - TD Cowen Maury Raycroft - Jefferies Derek Archila - Wells Fargo Mitchell Kapoor - H.C. Wainwright Operator Good day, everyone.
What Makes Kezar Life Sciences (KZR) a New Buy Stock
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial
The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths.
